Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals
| Autor: | Chiara Costa, Giuseppe Coppolino, Alessio Strazzulla, Laura Rivoli, Maria Concetta Postorino, Giorgio Settimo Barreca, Mariadelina Simeoni, Daniela Foti, Innocenza Gentile, Nadia Marascio, Giorgio Fuiano, Maria Mazzitelli, Vincenzo Pisani, Elio Gulletta, Carlo Torti, Alfredo Focà, Giuseppe Greco |
|---|---|
| Přispěvatelé: | Strazzulla, A., Coppolino, G., Barreca, G. S., Gentile, I., Rivoli, Lidia, Postorino, M. C., Mazzitelli, M., Greco, G., Costa, C., Pisani, V., Marascio, N., Simeoni, Anna, Focas, Germana, Fuiano, Laura, Foti, D., Gulletta, Salvatore, Torti, C., Rivoli, L., Simeoni, M., Foca, A., Fuiano, G., Gulletta, E. |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
Sofosbuvir 030232 urology & nephrology Hepacivirus medicine.disease_cause Kidney Gastroenterology Severity of Illness Index Hepatitis chemistry.chemical_compound 0302 clinical medicine Hepatitis C virus Acute Kidney Injury Middle Aged Antivirals Hepatitis C medicine.anatomical_structure RNA Viral 030211 gastroenterology & hepatology Original Article Female medicine.drug Glomerular Filtration Rate Human Ledipasvir medicine.medical_specialty Genotype Hepatiti Renal function Subgroup analysis Antiviral Agents 03 medical and health sciences Lipocalin-2 Internal medicine medicine Humans lcsh:RC799-869 Antiviral Molecular Biology Aged Inflammation Antiviral Agent Hepaciviru Hepatology business.industry Retrospective cohort study medicine.disease chemistry lcsh:Diseases of the digestive system. Gastroenterology business Hepatitis C viru |
| Zdroj: | Clinical and Molecular Hepatology, Vol 24, Iss 2, Pp 151-162 (2018) Clinical and Molecular Hepatology |
| Popis: | Background/Aims: Correct renal function evaluation is based on estimated glomerular filtration rates (eGFR) and complementary renal damage biomarkers, such as neutrophil gelatinase associated lipocalin (NGAL). The aim of this study was to evaluate eGFR and NGAL modifications and renal impairment during treatment with a direct acting antiviral (DAA) for chronic hepatitis C virus (HCV) infection. Methods: A retrospective cohort study evaluated eGFR modification during treatment with DAA. Subgroup analysis on serum NGAL was conducted in those receiving sofosbuvir/ledipasvir, with complete follow-up until week 12 after the end of treatment (FU-12). Results: In the 102 enrolled patients, eGFR reduction was observed (from 86.22 mL/min at baseline to 84.43 mL/min at FU-12, P=0.049). Mean NGAL increased in 18 patients (from 121.89 ng/mL at baseline to 204.13 ng/mL at FU-12, P=0.014). At FU-12, 38.8% (7/18) of patients had a plasmatic NGAL value higher than the normal range (36-203 ng/mL) compared with 11.1% (2/18) at baseline (χ2=3,704; P=0.054). In contrast, eGFR did not change significantly over the follow-up in this subgroup. Conclusions: In conclusion, compared to a negligible eGFR decline observed in the entire cohort analyzed, a significant NGAL increase was observed after HCV treatment with DAA in a small subgroup. This could reflect tubular damage during DAA treatment rather than glomerular injury. (Clin Mol Hepatol 2018;24:151-162) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|